BioSpace News Archive

Transparency Market Research has published a new report, titled, ‘Postoperative Pain Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027'. According to the postoperative pain therapeutics market report, the global postoperative pain therapeutics market was valued at US$ 11,459.3 Mn in 2018, and is projected to expand at a CAGR of nearly 4.5% from 2019 to 2027.

The drive for generic injectables has risen on the back of the recent fillip received by the generic pharmaceutical industry, fueled by the nearing patent expiry of several blockbuster drugs.

Barrett’s esophagus is one of the major complications of gastro-esophageal reflux disease in which the normal squamous tissue lining the esophagus changes to the tissue resembling that of the intestine lining.

Calliditas Therapeutics AB announced that the company now controls 100% of the share capital of Genkyotex SA, after the completion of a centralized squeeze out offer to all minority shareholders.

Maravai LifeSciences, Inc., a global provider of life science reagents and services to researchers and biotech innovators, announced that the European Patent Office has issued a new patent, No. 3352584, to the company’s TriLink BioTechnologies subsidiary.

New hires in Bioanalytical Sciences, Biostatistics, Clinical Regulatory, and Clinical Project Management will join the team of Drs. Srinivasan, Recknor, Ray, and Kelly to lead all clinical trials with new CROs

Second round application period open through December 31, 2021; up to three projects will be awarded AiCubator Resident Status and, over a period of up to three years, will benefit from expert scientific advice

Amgen and Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering precision medicines for brain diseases, announced a strategic collaboration to advance neuroscience discovery, development and commercialization.

Neumora Therapeutics, Inc., a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience, announced its launch.

Acquisition adds novel and proprietary SHIELD platform for conditional activation of antibodies in tumor microenvironment and proprietary cytotoxic payloads for antibody drug conjugates